Tau and Aβ imaging, CSF measures, and cognition in Alzheimer’s disease-Reference-Cited by-同舟云学术

Tau and Aβ imaging, CSF measures, and cognition in Alzheimer’s disease

Published:2016-05-11 Issue:338 Volume:8 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Brier Matthew R.¹,Gordon Brian²³,Friedrichsen Karl²,McCarthy John⁴,Stern Ari⁴,Christensen Jon²,Owen Christopher²,Aldea Patricia²,Su Yi²,Hassenstab Jason¹³,Cairns Nigel J.¹³⁵,Holtzman David M.¹³⁶,Fagan Anne M.¹³⁶,Morris John C.¹³⁵⁶,Benzinger Tammie L. S.²³⁷,Ances Beau M.¹²³⁶

Affiliation:

1. Department of Neurology, Washington University in St. Louis, St. Louis, MO 63110, USA.

2. Department of Radiology, Washington University in St. Louis, St. Louis, MO 63110, USA.

3. Knight Alzheimer’s Disease Research Center, Washington University in St. Louis, St. Louis, MO 63110, USA.

4. Department of Mathematics, Washington University in St. Louis, St. Louis, MO 63110, USA.

5. Department of Pathology, Washington University in St. Louis, St. Louis, MO 63110, USA.

6. Hope Center for Neurological Disorders, Washington University in St. Louis, St. Louis, MO 63110, USA.

7. Department of Neurosurgery, Washington University in St. Louis, St. Louis, MO 63110, USA.

Abstract

PET imaging of pathological tau correlates more closely with Alzheimer’s disease–related cognitive impairment than does imaging of β-amyloid.

Funder

NIH

NSF

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference51 articles.

1. Alzheimer's disease

2. Neuropathological stageing of Alzheimer-related changes

3. Phases of Aβ-deposition in the human brain and its relevance for the development of AD

4. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B

5. [11C]PIB in a nondemented population: Potential antecedent marker of Alzheimer disease

Cited by 586 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Digital cognitive assessments as low‐burden markers for predicting future cognitive decline and tau accumulation across the Alzheimer's spectrum;Alzheimer's & Dementia;2024-09-06

2. Alzheimer’s disease biomarkers and their current use in clinical research and practice;Molecular Psychiatry;2024-09-04

3. Strategies for measuring concentrations and forms of amyloid-β peptides;Biosensors and Bioelectronics;2024-09

4. Convergence of Accelerated Brain Volume Decline in Normal Aging and Alzheimer’s Disease Pathology;Journal of Alzheimer's Disease;2024-08-27

5. Deep learning assisted quantitative analysis of Aβ and microglia in patients with idiopathic normal pressure hydrocephalus in relation to cognitive outcome;Journal of Neuropathology & Experimental Neurology;2024-08-05